British American Tobacco’s response to FDA announcement
15 November 2018
In relation to the recent announcement from Commissioner Gottlieb, we share the FDA’s concerns around youth access to vapour products and we welcome the priority that he has given to this matter. However, in relation to his proposals on menthol cigarettes, the science today does not support treating them differently from other cigarettes.
Regarding youth access to vapour products:
We also share the FDA’s concern regarding balancing the importance of encouraging adult smokers to consider potentially reduced-risk alternatives to cigarettes – like vapour products – whilst ensuring that youth do not use them.
Whilst research shows that flavours play an important role in an adult smoker’s transition out of smoking, we understand the FDA’s concern that some flavours can play a role in increasing youth appeal. That is why we are happy to work with our nearly 200,000 contracted retail stores to address youth access to vapour products.
In relation to these vapour proposals we encourage the FDA to introduce enforceable regulations as soon as possible. Further, we encourage the FDA to bring forward the PMTA deadline earlier than 2022.
In relation to menthol cigarettes, while we will continue to engage with the FDA on its proposed plans, it is important to note that:
We will continue to work closely with the FDA on these important issues, including participating in a thorough science-based review to address the use of menthol in cigarettes. At the same time, we will continue to deploy our best efforts to curb youth access to vaping and tobacco products.
(Reference to Reynolds refers to the activities undertaken by one or more of companies that comprise the RAI group of companies)